BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $353.17M in the quarter ending September 30, 2026, with 192.60% growth. This brings the company's total for the last twelve months to $945.54M, up 167.27% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth. That makes BridgeBio Pharma the 7,909th largest company in the world by revenue and 1,837th in the United States.
Revenue (ttm)
$945.54M
Revenue Growth
+167.27%
P/S Ratio
15.75
Revenue / Employee
$871,465
Employees
1,085
Market Cap
14.96B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BridgeBio Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alnylam Pharmaceuticals | 5.01B |
| Jazz Pharmaceuticals | 4.72B |
| BioMarin Pharmaceutical | 3.66B |
| BioNTech SE | 2.75B |
| Exelixis | 2.50B |
| Halozyme Therapeutics | 1.80B |
| Madrigal Pharmaceuticals | 1.43B |
| Ascendis Pharma | 1.37B |
BBIO News
- 12 hours ago - Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM - GlobeNewsWire
- 1 day ago - BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - BridgeBio Pharma price target raised to $91 from $88 at Morgan Stanley - TheFly
- 6 days ago - BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026 - GlobeNewsWire
- 8 days ago - BridgeBio to Participate in November and December Investor Conferences - GlobeNewsWire
- 11 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 - GlobeNewsWire
- 15 days ago - BridgeBio Pharma price target raised to $108 from $106 at Canaccord - TheFly